JP2025509680A5 - - Google Patents
Info
- Publication number
- JP2025509680A5 JP2025509680A5 JP2024555003A JP2024555003A JP2025509680A5 JP 2025509680 A5 JP2025509680 A5 JP 2025509680A5 JP 2024555003 A JP2024555003 A JP 2024555003A JP 2024555003 A JP2024555003 A JP 2024555003A JP 2025509680 A5 JP2025509680 A5 JP 2025509680A5
- Authority
- JP
- Japan
- Prior art keywords
- weight
- approximately
- pharmaceutical composition
- composition according
- kinase inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263269330P | 2022-03-14 | 2022-03-14 | |
| US63/269,330 | 2022-03-14 | ||
| PCT/EP2022/058180 WO2022207580A2 (en) | 2021-03-27 | 2022-03-28 | Compositions having improved bioavailability of therapeutics |
| EPPCT/EP2022/058180 | 2022-03-28 | ||
| PCT/EP2023/056506 WO2023174948A2 (en) | 2022-03-14 | 2023-03-14 | Compositions having improved bioavailability of therapeutics and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025509680A JP2025509680A (ja) | 2025-04-11 |
| JP2025509680A5 true JP2025509680A5 (cg-RX-API-DMAC10.html) | 2026-03-24 |
Family
ID=85571360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024555003A Pending JP2025509680A (ja) | 2022-03-14 | 2023-03-14 | 治療薬のバイオアベイラビリティを改善した組成物およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4493151A2 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025509680A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2023233811A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3245873A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL315617A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023174948A2 (cg-RX-API-DMAC10.html) |
| ZA (1) | ZA202407659B (cg-RX-API-DMAC10.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4784247A1 (en) * | 2023-09-28 | 2026-08-05 | The Regents Of The University Of California | Methods and compositions of treating age-related conditions |
| WO2025093572A1 (en) * | 2023-10-29 | 2025-05-08 | TRx Biosciences Limited | Solid dispersion compositions and uses thereof |
| WO2026053168A1 (en) * | 2024-09-06 | 2026-03-12 | Graviton Bioscience Bv | Amorphous forms of a rock2 inhibitor and formulations thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5082667A (en) * | 1988-06-07 | 1992-01-21 | Abbott Laboratories | Solid pharmaceutical dosage in tablet triturate form and method of producing same |
| US5885486A (en) * | 1993-03-05 | 1999-03-23 | Pharmaciaand Upjohn Ab | Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof |
| US20020028813A1 (en) * | 1997-09-03 | 2002-03-07 | Paul F. Jackson | Thioalkyl compounds, methods, and compositions for inhibiting parp activity |
| US6063768A (en) | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
| US20060138059A1 (en) | 2004-12-28 | 2006-06-29 | Vair Larry L Jr | Corona-treated polypropylene liquid filtration media |
| JP5758630B2 (ja) * | 2007-11-15 | 2015-08-05 | エンメエッセディ・イタリア・エッセ・エッレ・エッレ | Parp阻害剤としてのピリダジノン誘導体 |
| EP2346495B2 (en) * | 2008-10-07 | 2023-05-24 | Kudos Pharmaceuticals Limited | Pharmaceutical formulation 514 |
| CN102307576A (zh) * | 2008-12-15 | 2012-01-04 | 班纳制药公司 | 用于增强水不溶性活性剂的释放和吸收的方法 |
| CN101507707B (zh) * | 2009-04-08 | 2011-01-19 | 邓菊娟 | 一种盐酸法舒地尔脂微球制剂及其制备方法 |
| CN101926757B (zh) * | 2010-09-01 | 2013-01-02 | 北京大学 | 一种难溶性药物的液体组合物及其制备方法 |
| CN102813639B (zh) * | 2011-06-08 | 2014-04-30 | 中国疾病预防控制中心寄生虫病预防控制所 | 甲苯达唑软胶囊剂 |
| US9073944B2 (en) * | 2012-02-21 | 2015-07-07 | Merck Patent Gmbh | Cyclic diaminopyrimidine derivatives |
| AU2014360537B2 (en) * | 2013-12-04 | 2017-09-07 | Gilead Sciences, Inc. | Methods for treating cancers |
| ES2975417T3 (es) * | 2017-03-03 | 2024-07-05 | Inspirna Inc | Formulaciones con estabilidad mejorada |
| WO2020079706A1 (en) * | 2018-10-15 | 2020-04-23 | Cipla Limited | Pharmaceutical formulation |
| WO2020217235A1 (en) * | 2019-04-24 | 2020-10-29 | Aizant Drug Research Solutions Private Limited | Solid dosage form of dasatinib |
| CN113546045B (zh) * | 2021-08-18 | 2022-11-11 | 浙江大学 | 恢复肿瘤微环境失活树突状细胞功能的纳米制剂及应用 |
-
2023
- 2023-03-14 AU AU2023233811A patent/AU2023233811A1/en active Pending
- 2023-03-14 CA CA3245873A patent/CA3245873A1/en active Pending
- 2023-03-14 JP JP2024555003A patent/JP2025509680A/ja active Pending
- 2023-03-14 WO PCT/EP2023/056506 patent/WO2023174948A2/en not_active Ceased
- 2023-03-14 EP EP23710760.2A patent/EP4493151A2/en active Pending
- 2023-03-14 IL IL315617A patent/IL315617A/en unknown
-
2024
- 2024-10-09 ZA ZA2024/07659A patent/ZA202407659B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024511208A5 (cg-RX-API-DMAC10.html) | ||
| JP6474732B2 (ja) | 激痛治療用組成物と方法 | |
| US10857114B2 (en) | Compositions and methods for treating severe pain | |
| US20140107206A1 (en) | Omega-3 pentaenoic acid compositions and methods of use | |
| ES2200182T3 (es) | Procedimiento de fabricacion de una mezcla de esteres. | |
| US9737500B2 (en) | Compositions and methods for treating severe pain | |
| JP2009108076A (ja) | リパーゼ阻害剤とショ糖脂肪酸エステルとを含む医薬組成物 | |
| JPH0714873B2 (ja) | 局所性製薬組成物 | |
| JP2003509357A (ja) | リパーゼ阻害剤を含有する分散処方物 | |
| USRE47316E1 (en) | Oral formulations of ospemifene | |
| WO2014158256A1 (en) | Omega-3 pentaenoic acid compositions and methods of use | |
| CN115364052B (zh) | 具有高载药量的中链甘油三酯的药物组合物及其相关方法 | |
| CN106256345A (zh) | 维生素c传递系统及其脂质体组合物 | |
| KR100533460B1 (ko) | 난용성 약물의 가용화용 점막흡착성 조성물, 이를 이용한난용성 약물의 가용화용 제형 및 이들의 제조 방법 | |
| CN104411295B (zh) | 敏感化组合物和使用方法 | |
| RU2582278C2 (ru) | Трансдермальное средство для лечения и профилактики болезней суставов и мягких тканей, способ его получения и комбинированный трансдермальный препарат для лечения и профилактики болезней суставов и мягких тканей | |
| JP3324264B2 (ja) | 鼻洗浄剤 | |
| CN110461325A (zh) | 包括口服或胃部施用依达拉奉的治疗 | |
| BRPI0618510A2 (pt) | formulação medicamentosa lìquida ou semi-sólida | |
| US11730709B2 (en) | Compositions and methods for treating severe pain | |
| WO1985004804A1 (fr) | Agent cholagogique/cholelithotriptique | |
| KR100524700B1 (ko) | 자가미세유화형 약물전달시스템을 이용한 고지혈증치료용약제 조성물 | |
| JP2006076958A (ja) | ネフローゼ症候群治療剤 | |
| KR100958892B1 (ko) | 대변 연화제 및 계면활성제를 함유하는 예비농축액 | |
| Holub | EPA/DHA |